DOCSLIB.ORG

Assay Menu & Statement of Qualifications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Assay Menu & Statement of Qualifications Your Global Biomarker Laboratory ASSAY MENU & STATEMENT OF QUALIFICATIONS ISSUE DATE AUG 25 , 2017 PREPARED FOR OUR VALUED CLIENTS EVE TECHNOLOGIES CORP HRIC 3A26 3330 Hospital Dr., N. W. Calgary, AB. Canada T2N 4N1 Eve Technologies 1 Your Global Biomarker Laboratory General Overview Eve Technologies offers the most affordable assay services in the world for biomedical and life science researchers, and pharmaceutical companies. Our assay services facilitate protein analysis and drug discovery by providing reproducible, quantitative immunoassay data from a small sample volume. We utilize multiplex assay platforms such as the Bio-Plex Suspension Array System and the Milliplex platform. Our target analyte menu offers hundreds of multiplexing targets under various categories such as Cytokines, Chemokines, Cardio Markers, Cancer Markers, and Neuroscience Markers. Key Service • Assay Service and Results • 800+ Targets (See below) • Species include Human, Mouse, Rat, Porcine, Canine, Feline, and Primate • Discovery Assay - Lowest price per analyte in the industry • Custom Multiplex options Why Eve Technologies? Experience With over 15 years of experience providing the world’s leading researchers with assay services and results, Eve Technologies has been instrumental in hundreds of published papers in some of the most respected journals. Eve Tech has become a leader in the industry assisting over 1000 research institutions with the best solutions for their projects. Our Assay service has become an important component in cost control in a research environment where money is hard to come by. Along with cost savings, Eve Technologies maintains high quality services on reputable assays. Expertise Specializing in Millipore (Milliplex) and Bio-Rad (Bio-Plex) systems these systems allow for Eve to perform up to 100 bioassays simultaneously on a single sample, these assays are efficient, cost effective and have high accuracy ratings. People Enough cannot be said about the employees of Eve Tech. Intelligent and committed, our staff takes pride in both what they do and their contribution to the research community. The team is composed of scientific professionals committed to the success of our client’s projects large or small. Please refer to our “Proposal” document or website for our profiles. Analyte By Category • Acute Phase Proteins •Diabetes and Obesity • Adipokine / Adipocyte •Endocrine • Angiogenesis •Gut Hormone • Apoptosis •Inflammation & Immunology • Autoimmune / Immunology •Isotyping • Bone Metabolism •Liver Biomarkers • Cancer Biomarkers •Kidney Biomarkers • Cardiovascular Disease •Metabolic Markers • Cellular Metabolism •Matrix Metallo-Proteinases • Cell Signaling •Neuroscience • Cytokines, Chemokines and Growth Factors •Pituitary and Thyroid 2 Eve Technologies TABLE OF CONTENTS iscovery D ® DISCOVERY ASSAY 04 A s s a y 07 AP ASSAY PANELS 18 HUMAN 25 RAT 27 MOUSE 30 PRIMATE 31 FELINE 32 PORCINE 33 CANINE 34 CONTACT Eve Technologies 3 ROUTINE DISCOVERY ASSAYS EGF IL-10 sCD30 sIL-6R Eotaxin-1 IL-12(p40) Human sEGFR sRAGE FGF-2 IL-12(p70) Soluble Cytokine sgp130 sTNFRI Flt-3L IL-13 Receptors sIL-1RI sTNFRII Fractalkine IL-15 14-Plex Array Discovery Price sIL-1RII sVEGFR1 G-CSF IL-17A $23.99/sample sIL-2Ra sVEGFR2 GM-CSF IL-18 sIL-4R sVEGFR3 GRO(pan) IP-10 IFNα2 MCP-1 Human { IFN MCP-3 MMP-1 MMP-12 Cytokine / Ɣ Chemokine IL-1α MDC MMP-2 MMP-13 42-Plex Array IL-1β MIP-1α Human MMP-3 TIMP-1 Discovery Price IL-1ra MIP-1β MMP & TIMP Array MMP-7 TIMP-2 $46.95/sample IL-2 PDGF-AA 13-Plex Array MMP-8 TIMP-3 Discovery Price IL-3 PDGF-AB/BB $23.95/sample MMP-9 TIMP-4 IL-4 RANTES MMP-10 IL-5 sCD40L IL-6 TGFα { IL-7 TNFα IL-8 TNFβ BDNF PDGF-AA IL-9 VEGF-A Human Cathepsin D PDGF-AB/BB Supplemental MPO RANTES Array NCAM sICAM-1 6Ckine IL-33 10-Plex PAI-1(total) sVCAM-1 BCA-1 LIF Discovery Price $21.59/sample {CTACK MCP-2 Human ENA-78 MCP-4 Secondary 23 Eotaxin-2 MIP-1d { Plex Array Angiopoietin-2 HB-EGF Combine with a Eotaxin-3 SDF-1α+β 41-Plex to make a I-309 SCF BMP-9 HGF 64-Plex EGF IL-8 Discovery Price IL-16 TARC Endoglin Leptin $26.95/sample IL-20 TPO Human IL-21 TRAIL Angiogenesis Endothelin-1 PlGF IL-23 TSLP 17-Plex Array FGF-1 VEGF-A Discovery Price FGF-2 VEGF-C IL-28A $25.19/sample Follistatin VEGF-D { { G-CSF GM-CSF IL-8 Human Adiponectin Lipocalin-2 /NGAL Human IFN฀ IL-10 Adipokine Cytokine Adipsin Resistin IL-1β IL-12(p70) (Serum/Plasma) Proinflammatory IL-2 IL-13 5-Plex Array PAI-1(total) 13-Plex Array Discovery Price Discovery Price IL-4 MCP-1 $17.39/sample $23.99/sample IL-5 TNF-α { { IL-6 4 Eve Technologies Eotaxin IL-13 G-CSF IL-15 GM-CSF IL-17A C-Peptide Insulin Human IFNƔ IP-10 Ghrelin Leptin Metabolic IL-1α KC 9-Plex Array GIP MCP-1 IL-1β LIF Discovery Price GLP-1 (active) PYY (total) Mouse $20.79/sample IL-2 LIX (unvalidated) Glucagon Cytokine / Chemokine IL-3 MCP-1 31-Plex Array IL-4 M-CSF Discovery Price IL-5 MIG $35.95/sample { IL-6 MIP-1α IL-7 MIP-1β GM-CSF IL-8 IL-9 MIP-2 Human IFNy IL-10 IL-10 RANTES High Sensitivity IL-1B IL-12p70 IL-12(p40) TNFα T-Cell Discovery IL-2 IL-13 Array 14-plex IL-12(p70) VEGF Discovery Price IL-4 IL-17A $24.69/sample IL-5 IL-23 IL-6 TNF-a { { EPO MDC 6Ckine MCP-5 Mouse Fractalkine MIP-3a TGF-β1 Cytokine Array / TGF-beta 3-Plex IFNB1 MIP-3B (Multi-Species) TGF-β2 Chemokine Array 13-plex Secondary IL-11 TARC 3-Plex Array TGF-β3 Discovery Price Panel IL-16 TIMP-1 Discovery Price $16.39/sample IL-20 { $23.99/sample { Steroid/Thyroid IL-17A IL-27 for non-blood IL-17E IL-28B based samples Mouse Cortisol IL-17F IL-31 (STTD-Cell/ Mouse Th17 Tissue) Estradiol 11-Plex IL-21 IL-33 (Multi-Species) Progester- Discovery Price IL-22 MIP-3a 5-Plex Array $22.19/sample IL-23 Discovery Price T3 $19.99/sample { T4 { GM-CSF IL-6 Steroid/ Thyroid for IFNy IL-10 Cortisol Serum, Plasma, Mouse IL-1B IL-12p70 Whole blood Estradiol Cytokine Array Proin- flammatory Focused IL-2 MCP-1 (STTHD-Serum/ Progester- Plasma) 10-plex IL-4 TNF-a (Multi-Species) T3 Discovery Price 5-Plex Array T4 $21.99/sample Discovery Price Price includes special $31.99/sample { extraction step. { Eve Technologies 5 MMP-2 MMP-2 Mouse MMP-3 Mouse MMP-3 MMP Discovery Array MMP-8 MMP Discovery Array MMP-8 5-plex 5-plex (Serum & Plasma) proMMP-9 (Cell Culture and non- proMMP-9 Discovery Price MMP-12 blood samples) MMP-12 $17.39/sample Discovery Price { $17.39/sample { Eotaxin IL-12(p70) EGF IL-13 Fractalkine IL-17A Amylin (active)* Insulin G-CSF IL-18 C-Peptide 2 Leptin GM-CSF IP-10 GIP(total) PP Mouse and Rat Rat GRO/KC Leptin GLP-1(active)* PYY Metabolic Array Cytokine / IFN LIX Ɣ Resistin Chemokine 11-Plex Array Ghrelin(active)* (Mouse Only) 27-Plex Array IL-1α MCP-1 Discovery Price Discovery Price IL-1β MIP-1α $22.19/sample Glucagon* $31.95/sample IL-2 MIP-2 * Inhibitors Recommended IL-4 RANTES { IL-5 TNF-α IL-6 VEGF {IL-10 GM-CSF IL-6 IFNƔ IL-8 Porcine IL-1α IL-10 Cytokine IL-1β IL-12 13-Plex Array Discovery Price IL-1ra IL-18 $23.99/sample IL-2 TNF-α { IL-4 For a full list of our Discovery Assay’s please see our website No Minimum Sample Order 6 Eve Technologies Choose your Assay Send your Sample Get Results! HUMAN Human Cytokine/Chemokine Human Th17 Immunology Panel IV GM-CSF IL-17E / IL-25 Human Cytokine/Chemokine APRIL / TNFSF13 IL-28B / IFNλ3 IFNγ IL-17F Panel I BAFF / Blys IL-32α IL-1β IL-21 BRAK / CXCL14 IL-34 IL-2 IL-22 CCL28 IL-35 IL-4 IL-23 sCD40L IL-9 CXCL16 IL-36β / IL-1F8 IL-5 IL-27 EGF ♦ IL-10 ♦ HCC-4 / CCL16 IL-37 / IL-1F7 IL-6 IL-28A / IFNλ2 Eotaxin / CCL11 ♦ IL-12 (p40) ♦ HMGB1 ● IL-38 / IL-1F10 IL-9 IL-31 FGF-2 / FGF-basic IL-12 (p70) ♦ IL-10 IL-33 / NF-HEV ♦ IFNβ MIP-4 / PARC / CCL18 Flt3 Ligand IL-13 (mature) IL-14 / α-Taxilin MPIF / CCL23 IL-12 (p70) Fractalkine / CX3CL1 IL-15 ♦ IL-13 MIP-3α / CCL20 ♦ ♦ IL-19 YKL40/CHI3L1 G-CSF IL-17A / CTLA8 TNFα IL-24 IL-15 GM-CSF ♦ IP-10 / CXCL10 ♦ IL-17A / CTLA8 TNFβ/Lymphotoxinα GRO MCP-1 / CCL2 ♦ (LTA) IFNα2 ♦ MCP-3 / CCL7 Human High Sensitivity IFNγ ♦ MDC / CCL22 Human CD8+ T Cell IL-1α ♦ MIP-1α / CCL3 ♦ T Cell IL-1β ♦ MIP-1β / CCL4 ♦ IL-1Ra ♦ PDGF-AA ▲ Fractalkine / CX3CL1 IL-12 (p70) ♦ sCD137/4-1BB/ IL-4 IL-2 ♦ PDGF-AB / BB ▲ TNFRSF9 GM-CSF ♦ IL-13 ♦ IL-5 IL-3 ♦ RANTES / CCL5 ♦▲ sFAS / TNFRSF6 IFNγ ♦ IL-17A / CTLA8 IL-6 IL-4 ♦ TGFα sFasL IL-1β ♦ IL-21 IL-10 IL-5 ♦ TNFα ♦ GM-CSF IL-2 ♦ IL-23 IL-13 IL-6 ♦ TNFβ / Lymphotoxin-A Granzyme A IL-4 ♦ I-TAC / CXCL11 MIP-1α / CCL3 IL-7 ♦ (LTA) ♦ Granzyme B MIP-1β / CCL4 VEGF-A ♦ IL-5 ♦ MIP-1α / CCL3 IL-8 / CXCL8 ♦ IFNγ IL-6 ♦ MIP-1β / CCL4 Perforin IL-2 IL-7 ♦ MIP-3α / CCL20 TNFα IL-8 / CXCL8 ♦ TNFα ♦ IL-10 ♦ Human Cytokine/Chemokine Human Complement Panel 1 Panel II Human Soluble Cytokine Receptor Adipsin/Factor D C5a C2 C9 6Ckine/CCL21/ IL-28A/IFNλ2 C4b Factor I Exodus-2 IL-33/NF-HEV C5 Mannose-binding BCA-1/CXCL13 (mature) sCD30 sIL-6R CTACK/CCL27 LIF sEGFR sRAGE Lectin (MBL) ENA-78/CXCL5 MCP-2/CCL8 sgp130 sTNF RI Eotaxin-2/CCL24/ MCP-4/CCL13 sIL-1RI sTNF RII Human Complement Panel 2 MPIF-2 MIP-1δ/MIP-5/CCL15 sIL-1RII sVEGFR1 / sFlt-1 Eotaxin-3/CCL26 sVEGFR2 / sKDR / sFlk-1 SCF sIL-2Rα I-309/CCL1 SDF-1/CXCL12 sVEGFR3 / sFlt-4 sIL-4R C1q Factor B IL-16 TARC/CCL17 C3 Factor H IL-20 TPO C3b / iC3b Factor P/Properdin IL-21 TRAIL/TNFSF10 C4 IL-23 TSLP Human MMP Panel 1 Human Cytokine/Chemokine Panel III MMP-3 MMP-13 MMP-12 HCC-1 / CCL14 ▲ M-CSF/CSF-1 Human MMP Panel 2 IL-11 MIG / CXCL9 IL-29 / IFNλ1 MIP-3α / CCL20 I-TAC / CXCL11 MIP-3β / CCL19 MMP-1 MMP-9 LIX / CXCL6 / GCP-2 NAP-2 / CXCL7 ▲ MMP-2 MMP-10 Lymphotactin / XCL1 MMP-7 Eve Technologies 7 Human TIMP Panel 1 Human Skin (Serum/Plasma samples) (Skin extracts only) Human Diabetes ▼
Load more

Recommended publications
  • Mechanism of Satellite Cell Regulation by Myokines
    J Phys Fitness Sports Med, 6 (5): 311-316 (2017) DOI: 10.7600/jpfsm.6.311 JPFSM: Review Article Mechanism of satellite cell regulation by myokines Yasuro Furuichi* and Nobuharu L. Fujii Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, 1-1 Minami-Osawa, Hachioji, Tokyo 193-0397, Japan Received: July 19, 2017 / Accepted: August 7, 2017 Abstract Skeletal muscle stem cells, known as satellite cells, participate in postnatal skeletal muscle growth, regeneration, and hypertrophy. They are quiescent in the resting state, but are activated after muscle injury, and subsequently replicate and fuse into existing myofibers. The behavior of satellite cells during muscle regeneration is regulated by extrinsic factors, such as the extracellular matrix, mechanical stimuli, and soluble factors. Myokines, muscle-derived secretory factors, are important regulators of satellite cell activation, proliferation, and differen- tiation. It is well known that muscle injury induces the release of various growth factors from myofibers, and these growth factors affect satellite cells. It has recently been shown that myo- kines secreted from myofibers without cell damage also regulate satellite cell functions. Here, we summarize myokines with known roles in the regulation of satellite cells and the mecha- nism underlying this regulatory process. Keywords : secretion, myogenesis, muscle regeneration regulation, but there are also molecules related to muscle Introduction regeneration or plasticity. In this review, we introduce the Skeletal muscle is a unique tissue that has a remarkable reported myokines involved in the regulation of satellite ability to regenerate after injury. In response to tissue cell behavior and its molecular mechanism.
    [Show full text]
  • Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications
    International Journal of Molecular Sciences Review Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications Sandra Maria Barbalho 1,2,3,* , Uri Adrian Prync Flato 1,2 , Ricardo José Tofano 1,2, Ricardo de Alvares Goulart 1, Elen Landgraf Guiguer 1,2,3 , Cláudia Rucco P. Detregiachi 1 , Daniela Vieira Buchaim 1,4, Adriano Cressoni Araújo 1,2 , Rogério Leone Buchaim 1,5, Fábio Tadeu Rodrigues Reina 1, Piero Biteli 1, Daniela O. B. Rodrigues Reina 1 and Marcelo Dib Bechara 2 1 Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marilia (UNIMAR), Avenue Hygino Muzzy Filho, 1001, Marília 17525-902, São Paulo, Brazil; urifl[email protected] (U.A.P.F.); [email protected] (R.J.T.); [email protected] (R.d.A.G.); [email protected] (E.L.G.); [email protected] (C.R.P.D.); [email protected] (D.V.B.); [email protected] (A.C.A.); [email protected] (R.L.B.); [email protected] (F.T.R.R.); [email protected] (P.B.); [email protected] (D.O.B.R.R.) 2 School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17506-000, São Paulo, Brazil; [email protected] 3 Department of Biochemistry and Nutrition, Food Technology School, Marília 17525-902, São Paulo, Brazil 4 Medical School, University Center of Adamantina (UniFAI), Adamantina 17800-000, São Paulo, Brazil 5 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo (FOB–USP), Alameda Doutor Octávio Pinheiro Brisolla, 9-75, Bauru 17012901, São Paulo, Brazil * Correspondence: [email protected]; Tel.: +55-14-99655-3190 Received: 6 May 2020; Accepted: 19 May 2020; Published: 20 May 2020 Abstract: Skeletal muscle is capable of secreting different factors in order to communicate with other tissues.
    [Show full text]
  • Gut Microbiota and Regulation of Myokine-Adipokine Function
    Available online at www.sciencedirect.com ScienceDirect Gut microbiota and regulation of myokine-adipokine function 1 1 Francesco Suriano , Matthias Van Hul and Patrice D Cani Both skeletal muscle and adipose tissue are considered as particular interest on how they affect metabolic homeosta- endocrine organs due to their ability to produce and secrete sis of the whole body. several bioactive peptides (e.g. myokines and adipokines). Those bioactive molecules are well known for their capacity to Myokines influence whole-body homeostasis and alterations in their In the body, there are different type of muscles (skeletal, production/secretion are contributing to the development of cardiac,smooth),whichperform different functions based on various metabolic disorders. While it is well accepted that their location. They are mainly responsible for maintaining changes in the composition and functionality of the gut and changing body posture, producing force and motion, microbiota are associated with the onset of several generating heat (both through shivering and non-shivering), pathological disorders (e.g. obesity, diabetes, and cancer), its as well as facilitating movement of internal organs, such as contribution to the regulation of the myokine-adipokine profile the heart, digestive organs, and blood vessels [2,3]. Skeletal and function remains largely unknown. This review will focus on muscle is the largest organ in the human body, accounting for myokines and adipokines with a special interest on their about 30% of body mass in women and 40% in men, though interaction with the gut microbiota. muscle mass is affected by several conditions such as fasting, physical inactivity, cancer, obesity, untreated diabetes, hor- Address monal changes, heart failure, AIDS, chronic obstructive UCLouvain, Universite´ catholique de Louvain, WELBIO - Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research pulmonary disease (COPD), or aging [4].
    [Show full text]
  • Exercise-Released Myokines in the Control of Energy Metabolism Claire Laurens, Audrey Bergouignan, Cedric Moro
    Exercise-Released Myokines in the Control of Energy Metabolism Claire Laurens, Audrey Bergouignan, Cedric Moro To cite this version: Claire Laurens, Audrey Bergouignan, Cedric Moro. Exercise-Released Myokines in the Control of En- ergy Metabolism. Frontiers in Physiology, Frontiers, 2020, 10.3389/fphys.2020.00091. hal-02868660 HAL Id: hal-02868660 https://hal.archives-ouvertes.fr/hal-02868660 Submitted on 15 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. fphys-11-00091 February 11, 2020 Time: 18:13 # 1 MINI REVIEW published: 13 February 2020 doi: 10.3389/fphys.2020.00091 Exercise-Released Myokines in the Control of Energy Metabolism Claire Laurens1,2, Audrey Bergouignan1,3 and Cedric Moro4,5* 1 CNRS, IPHC, UMR 7178, Université de Strasbourg, Strasbourg, France, 2 Centre National d’Etudes Spatiales, Paris, France, 3 Division of Endocrinology, Metabolism and Diabetes, Anschutz Health & Wellness Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 4 INSERM, UMR 1048, Obesity Research Laboratory, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France, 5 Paul Sabatier University, University of Toulouse, Toulouse, France Physical activity reduces cardiometabolic risk, while physical inactivity increases chronic diseases risk.
    [Show full text]
  • The Diseasome of Physical Inactivity – and the Role of Myokines in Muscle–Fat Cross Talk
    J Physiol 587.23 (2009) pp 5559–5568 5559 SYMPOSIUM REVIEW The diseasome of physical inactivity – and the role of myokines in muscle–fat cross talk Bente K. Pedersen The Centre of Inflammation and Metabolism at the Department of Infectious Diseases, and Copenhagen Muscle Research Centre, Rigshospitalet, the Faculty of Health Sciences, University of Copenhagen, Denmark Type 2 diabetes, cardiovascular diseases, colon cancer, breast cancer, dementia and depression constitute a cluster of diseases, which defines ‘a diseasome of physical inactivity’. Both physical inactivity and abdominal adiposity, reflecting accumulation of visceral fat mass, are associated with the occurrence of the diseases within the diseasome. Physical inactivity appears to be an independent and strong risk factor for accumulation of visceral fat, which again is a source of systemic inflammation. Chronic inflammation is involved in the pathogenesis of insulin resistance, atherosclerosis, neurodegeneration and tumour growth. Evidence suggests that the protective effect of exercise may to some extent be ascribed to the anti-inflammatory effect of regular exercise, which can be mediated via a reduction in visceral fat mass and/or by induction of an anti-inflammatory environment with each bout of exercise. The finding that muscles produce and release myokines provides a conceptual basis to understand the mechanisms whereby exercise influences metabolism and exerts anti-inflammatory effects. According to our theory, contracting skeletal muscles release myokines, which work in a hormone-like fashion, exerting specific endocrine effects on visceral fat. Other myokines work locally within the muscle via paracrine mechanisms, exerting their effects on signalling pathways involved in fat oxidation. (Received 28 July 2009; accepted after revision 10 September 2009; first published online 21 September 2009) Corresponding author B.
    [Show full text]
  • Dynamic Approaches to Improve Glycemic Control and Primary Diabetes Care 1‑Or 2‑Or 3‑Or
    DYNAMIC APPROACHES TO IMPROVE GLYCEMIC CONTROL AND PRIMARY DIABETES CARE DYNAMIC APPROACHES TO IMPROVE GLYCEMIC Figure. CONTROL AND PRIMARY DIABETES CARE 1‑OR Characterizing Clinical Inertia in a Large, National Database CORI R. RATTELMAN, ANUPAMA ARORA, JOHN K. CUDDEBACK, ELIZABETH L. CIEMINS, Alexandria, VA Objective: To characterize clinical inertia in the treatment of diabetes using a large, geographically diverse clinical database. Study Design: A retrospective descriptive analysis was conducted in a clinical database containing 22 million patient records across 22 health care organizations (HCOs). Population Studied: A total of 281,000 patients aged 18-75 were included during the 5.5-year study period (1/2012-6/2017). Patients had an outpatient visit in the last 12 months of the study period, an HbA1c in the last 24-30 months (index A1c), and a diagnosis of type 2 DM on a claim or EHR prob- lem list at least 6 months prior to index A1c. A subset of 47,693 patients with an index A1c ≥8 and a prior A1c ≥8 or lack thereof, was observed for Supported By: National Institute of Diabetes and Digestive and Kidney Diseases four 6-month follow-up periods for actions including a new class of diabetes (T35DK104689); Yale University medication prescribed or an A1c <8. The absence of observable action fol- lowing index A1c suggests potential “clinical inertia.” Principal Findings: Six months following an index A1c≥8, 55% of patients 3‑OR received no observable clinical action ranging from 45-65% across HCOs Influence of Diabetes Complications on the Cost‑Effectiveness of and 18-96% across individual providers.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.450,069 B2 Goix Et Al
    USOO8450069B2 (12) United States Patent (10) Patent No.: US 8.450,069 B2 Goix et al. (45) Date of Patent: May 28, 2013 (54) HIGHLY SENSITIVE BIOMARKERPANELS 5,645,702 A 7, 1997 Witt et al. 5,653,859 A 8, 1997 Parton et al. 0. Y8 5,653,939 A 8, 1997 Hollis et al. (75) Inventors: E.obert Puskas, RER Manchester, v. (US);G. 5,681,7515,658.413 A 10/19978/1997 KaltenbachBegg et al. et al. John Todd, Lafayette, CA (US); 5,682,038 A 10/1997 Hoffman Richard Livingston, Webster Groves, 5,716,825 A 2/1998 Hancocket al. MO (US); Douglas Held, Ballwin, MO 37:6 A Eal (US); Sara Le, Berkeley, CA (US) 5,755,942 A 5/1998 ZanzucchiaC ( a. et al. 5,770,029 A 6/1998 Nelson et al. (73) Assignee: Singulex, Inc., Alameda, CA (US) 5,793.485 A 8, 1998 GE, al 5,795,158 A 8, 1998 Warinner (*) Notice: Subject to any disclaimer, the term of this 5,795,758 A 8/1998 Gentry et al. patent is extended or adjusted under 35 38.7 A s 3. E. tal U.S.C. 154(b) by 0 days. 5,858,195 A 1/1999 Ramsey1gen et al. 5,863,801 A 1/1999 Southgate et al. (21) Appl. No.: 12/795,414 5,925,533. A 7/1999 Doth et al. 5,949,532 A 9, 1999 Schrofetal. (22) Filed: Jun. 7, 2010 5,955,028 A 9, 1999 Chow 5,989.402 A 1 1/1999 Chow et al.
    [Show full text]
  • Biomarker Assay LUMINEX ELISA
    Biomarker Assay LUMINEX ELISA Test your samples Have your data MILAN – OXFORD – SAN DIEGO HQ Via Apelle, 41 – 20128 – Italy RO Via Ranzato, 12 – 20128 – Italy W labospace.com @ [email protected] T +39 02 35980841 F +39 02.2572231 PI IT 07312350965, REA Milano 1951817 del 16/02/2011 Biomarker Testing Service Luminex Multiparameter & ELISA Testing Service Biomarker multiplex immunoassays service offered by Labospace is an high efficient tools for measuring the levels of multiple proteins in a single sample volume, tipically 10-50uL using Luminex technology. Using our service means: • Enables you to obtain reproducible, quantitative high-quality data from a small volume • Receive high-quality assay/data feedback with reports created by experienced professionals • Optimize your time and resources to focus on other projects •Most flexible and accurate multiplex assay service available. •User-friendly ordering tool with the support of our expertise team •Build your own panel from over 800 analytes. •Available as ready to go multifactor panels as well as custom made panels Execution under ISO regulatory SOPS LABOSPACE.COM M COM 703 REV00 How it works Contact [email protected] and tell your needs Discuss our proposal and define the panel SOW generation and approval in order to meet your expectations Prepare the assay layout, with or without the Labospace’s support team, and provide the data in the template provided. The Labospace team will organize the data pick up and prepare the documentation for your laboratory.- Data Delivery High Throughput capability 384 well plate on Human Multi-Combo Screening 65 analytes Mouse Multi-Combo Screening 48 analytes LABOSPACE.COM M COM 703 REV00 Panels Available Cat.
    [Show full text]
  • Increased Adipose Tissue Expression of Interferon Regulatory Factor (IRF)-5 in Obesity: Association with Metabolic Inflammation
    cells Article Increased Adipose Tissue Expression of Interferon Regulatory Factor (IRF)-5 in Obesity: Association with Metabolic Inflammation Sardar Sindhu 1,* , Reeby Thomas 2, Shihab Kochumon 2, Ajit Wilson 2, Mohamed Abu-Farha 3 , Abdullah Bennakhi 4, Fahd Al-Mulla 5 and Rasheed Ahmad 2,* 1 Animal & Imaging Core Facility, Dasman Diabetes Institute (DDI), Al-Soor Street, P.O. Box 1180, Dasman 15462, Kuwait 2 Department of Microbiology & Immunology, Dasman Diabetes Institute (DDI), Al-Soor Street, P.O. Box 1180, Dasman 15462, Kuwait; [email protected] (R.T.); [email protected] (S.K.); [email protected] (A.W.) 3 Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Al-Soor Street, P.O. Box 1180, Dasman 15462, Kuwait; [email protected] 4 Medical Division, Dasman Diabetes Institute (DDI), Al-Soor Street, P.O. Box 1180, Dasman 15462, Kuwait; [email protected] 5 Department of Genetics & Bioinformatics, Dasman Diabetes Institute (DDI), Al-Soor Street, P.O. Box 1180, Dasman 15462, Kuwait; [email protected] * Correspondence: [email protected] (S.S.); [email protected] (R.A.); Tel.: +965-2224-2999 (ext. 4332) (S.S.); +965-2224-2999 (ext. 4311) (R.A.); Fax: +965-2249-2406 (S.S. & R.A.) Received: 6 October 2019; Accepted: 6 November 2019; Published: 11 November 2019 Abstract: Interferon regulatory factor (IRF)-5 is known to be involved in M1 macrophage polarization, however, changes in the adipose expression of IRF5 in obesity and their relationship with the local expression of proinflammatory cytokines/chemokines are unknown. Therefore, IRF5 gene expression was determined in the subcutaneous adipose tissue samples from 53 non-diabetic individuals (6 lean, 18 overweight, and 29 obese), using real-time RT-PCR.
    [Show full text]
  • 09.Subjectindex ADA 13.Indd
    SUBJECT INDEX (-)-Epigallocatechin-3-gallate 2919-PO Add-on to basal insulin 1102-P Aggressiveness factor 2526-PO 1,5-Anhydroglucitol 928-P Add-on to metformin 1092-P Aging 1284-P, 1396-P, 1399-P, 1797-P, 1966-P, 11 β-HSD 1993-P Add-on to metformin + SU 1082-P 1972-P, 1981-P, 2007-P, 2209-P, 2308-PO, 11beta-HSD, glucocorticosteroids, type 2 diabetes Add-on to pioglitazone 1120-P 2481-PO, 2693-PO, 2697-PO 1128-P Adenine nucleotide translocase 28-OR, 29-OR Aging society 2657-PO 11β-HSD1 1875-P Adenosine A1 receptor 1854-P Agreement 2508-PO SUBJECT INDEX 12(S)-HETE 2057-P Adenovirus, shrna, over expression 340-OR Agrp neurons 1917-P 12/15-Lipoxygenase 2057-P Adherence 652-P, 789-P, 802-P, 814-P, 821-P, 857-P, AICAR 1815-P 12-Lipoxygenase 338-OR 889-P, 894-P, 1227-P, 1259-P, 1423-P, 2504-PO Akita 1643-P 14-3-3 142-OR Adhesive capsulitis 2887-PO Akt 25-OR 18FDG PET 2026-P Adipocyte 100-OR, 1644-P, 1748-P, 1748-P, 1749-P, Akt mediated signaling pathway 2321-PO 18F-TTCO-cys40-exendin-4 2163-P 1751-P, 1752-P, 1755-P, 1756-P, 1758-P, 1761-P, Akt, glucose uptake 1802-P 1-h plasma glucose 1457-P, 2808-PO 1763-P, 1765-P, 1769-P, 1769-P, 2056-P, 2943-PO Akt/GSK3 signaling pathway 488-P 25(OH)D 679-P Adipocyte differentiation 144-OR, 1745-P, 1745-P, Akt2 1818-P 25-hydroxivitamin D 2035-P 2013-P Alanine 1916-P 26S Proteasomes 498-P Adipocyte fatty acid-binding protein 2003-P Alanine aminotransferase 1460-P, 2860-PO 2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid Adipocyte precursor cells 2081-P Alaska native people 183-OR 2079-P Adipocytes 94-OR, 95-OR,
    [Show full text]
  • Irisin Regulated Bone Metabolism in Gain-Of- and Loss-Of-Function Mouse Models
    Irisin Regulated Bone Metabolism in Gain-of- and Loss-of-function Mouse Models Xiaofang Zhu1, 2, Qisheng Tu1, Jin Zhang1, Guofang Shen2, Jake Jinkun Chen1 Introduction Irisin, a recently identified novel hormone-like myokine, is the cleaved and secreted portion of fibronectin-type III domain-containing 5 (FNDC5). It was initially reported that irisin plays an important role in converting the white adipose tissue (WAT) to brown adipose tissue (BAT) and regulating energy expenditure (Boström et al. 2012). Recent studies also reported the involvement of irisin in many other physiological and pathological conditions, such as type II diabetes mellitus (T2DM) (Zhang et al. 2014), renal disease (Ebert et al.2014), hippocampal neurogenesis (Curlik et al. 2013), and osteoporotic fractures (Anastasilakis et al. 2014). In our previous study, increased levels of irisin were found in different regions of femoral bones in exercising mice, and that leads us to hypothesize that irisin regulates bone metabolism. In this study, we explore the effects of myokine irisin in bone formation and further established an irisin knockout mouse line to determine the mechanisms of irisin regulating bone metabolism. Materials and Methods Cell culture experiments. MC3T3-E1 cells (ATCC, Manassas, VA) were cultured with osteogenic induction. MC3T3-E1 cells were serum-starved overnight and then treated with 50 µg/ml of ascorbic acid (AA) in the presence or absence of irisin for 7, 10 and 14 days. The formation of bone nodules was monitored by alizarin red staining followed by 1 Division of Oral Biology, School of Dental Medicine, Tufts University, Boston, Massachusetts, UNITED STATES 2 Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA melting bone nodules with 10% (v/v) cetylpyridinium chloride and determination of absorbance at 562 nm.
    [Show full text]
  • The Myokine Irisin Is Released in Response to Saturated Fatty Acids and Promotes Pancreatic B-Cell Survival and Insulin Secretion
    Diabetes Volume 66, November 2017 2849 The Myokine Irisin Is Released in Response to Saturated Fatty Acids and Promotes Pancreatic b-Cell Survival and Insulin Secretion Annalisa Natalicchio,1 Nicola Marrano,1 Giuseppina Biondi,1 Rosaria Spagnuolo,1 Rossella Labarbuta,1 Immacolata Porreca,2 Angelo Cignarelli,1 Marco Bugliani,3 Piero Marchetti,3 Sebastio Perrini,1 Luigi Laviola,1 and Francesco Giorgino1 Diabetes 2017;66:2849–2856 | https://doi.org/10.2337/db17-0002 This study explored the role of irisin as a new pancreatic correlate with markers of insulin resistance in subjects with- b-cell secretagogue and survival factor and its potential out diabetes, while they are reduced in overt type 2 diabetes role in the communication between skeletal muscle and (2,3). The biological functions of irisin include effects on pancreatic b-cells under lipotoxic conditions. Recombi- multiple tissues (1,4–7). Irisin also improves glucose toler- nant irisin stimulated insulin biosynthesis and glucose- ance and insulin sensitivity and increases energy expendi- stimulated insulin secretion (GSIS) in a PKA-dependent ture in both obese and diabetic mice (8). Irisin increases ISLET STUDIES – manner and prevented saturated fatty acid induced apo- proliferation of insulin-secreting INS-1E cells and protects b ptosis in human and rat pancreatic -cells, as well as in them from high glucose–induced apoptosis (9). human and murine pancreatic islets, via AKT/BCL2 signal- If chronically in excess, saturated free fatty acids (FFAs) ing. Treatment of myotubes with 0.5 mmol/L palmitate for can reduce insulin biosynthesis (10) and secretion (11) and 4 h, but not with oleate, promoted an increase in irisin promote b-cell apoptosis (12,13).
    [Show full text]